ハギワラ　ノブヒサ   Nobuhisa Hagiwara   萩原　誠久    所属   その他 その他    職種   非常勤嘱託
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Effectiveness and safety of dabigatran versus warfarin in real-world Japanese patients with atrial fibrillation: A single-center observational study
掲載誌名	正式名：Journal of Arrhythmia 略　 称：J Arrhythmia ISSNコード：1880-4276/1883-2148
掲載区分	国内
出版社	Japanese Heart Rhythm Society
巻・号・頁	33(2),pp.107-110
著者・共著者	NAGANUMA Miyoko†, SHIGA Tsuyoshi*, NAGAO Takehiko, SUZUKI Atsushi, MURASAKI Kagari, HAGIWARA Nobuhisa
担当区分	最終著者
発行年月	2017/04
概要	BACKGROUND: In "real-world" practice, anticoagulant therapy is indicated for patients whose clinical profiles are not addressed in randomized clinical trials. We assessed the effectiveness and safety of dabigatran versus warfarin in "real-world" Japanese patients with non-valvular atrial fibrillation (NVAF). METHODS: Among 613 NVAF patients who initiated dabigatran or warfarin therapy during the period between 2011 and 2013, 362 patients were included in the study after propensity score adjustment. The median follow-up period was 1.3 years. The effectiveness and safety outcomes were thromboembolism and major bleeding, respectively. RESULTS: The propensity-matched hazard ratios of thromboembolism and major bleeding with dabigatran were 1.03 (95% CI: 0.12-8.04, p=0.971) and 0.15 (95% CI: 0.01-0.90, p=0.037), respectively. CONCLUSIONS: The ability of dabigatran to prevent thromboembolism is comparable to that of warfarin; however, the major bleeding rate is lower with dabigatran in "real-world" NVAF patients.
DOI	http://dx.doi.org/10.1016/j.joa.2016.07.007
PMID	28416975